Danazol and Hemophilia

William E. Hathaway
In: JAMA: The Journal of the American Medical Association · 1985 · vol. 253(8) , pp. 1167 · doi:10.1001/jama.1985.03350320091025 · PMID:3968846 · W1997919174
editorial OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper discusses evidence suggesting danazol administration is associated with increased levels of factor VIIIc and factor IX, and decreased transfusion needs in hemophilia patients, though its usefulness remains debated.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol is a 2,3-isoxazol derivative of 17 α-ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, α1-antitrypsin, and Cl esterase inhibitor.1,2Last year Gralnick and Rick1reported evidence that danazol was associated with increased levels of factor VIIIc and factor IX and decreased transfusion requirements in patients with hemophilia. Subsequent studies by Gralnick and associates4as well as other studies by Garewal et al5are reported in this issue ofThe Journaland form the basis for this commentary. The readers of the aforementioned articles are faced with a dilemma in judging the usefulness of danazol in management of hemophilia patients. Gralnick et al report on three of their initial patients plus eight French patients with hemophilia A.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (7)

Source provenance

openalex
last seen: 2026-05-11T04:27:18.596339+00:00
License: CC0 · commercial use OK